Subscribe to RSS
DOI: 10.1055/s-2001-14096
© Georg Thieme Verlag Stuttgart · New York
Prädiktion und Prävention des Typ-1-Diabetes
Prediction and prevention of type 1 diabetesPublication History
Publication Date:
31 December 2001 (online)

Die klinische Manifestation des Typ-1-Diabetes mellitus ist der Endpunkt einer Entzündung und autoimmunen Zerstörung der insulinproduzierenden Betazellen des Pankreas. Bereits viele Jahre vor Ausbruch der Erkrankung treten bei Betroffenen Insel-Autoantikörper auf, die in Venen- oder Kapillarblut detektierbar sind. Dies ermöglicht eine frühzeitige Diagnose der Autoimmunerkrankung noch vor dem Auftreten von klinischen Symptomen der Hyperglykämie.
In der vorliegenden Übersicht werden Strategien der Früherkennung diskutiert und Empfehlungen zum Einsatz von immunologischen, genetischen bzw. metabolischen Markern zur Risikoabschätzung des Typ-1-Diabetes gegeben. Des weiteren werden laufende Studien zur Prävention des Typ-1-Diabetes vorgestellt.
Literatur
- 1 Akerblom H J, Virtanen S M, Hämäläinen. et al .Modulation of the appearance of diabetes
associated autoantibodies in the nutritional prevention of type
1 diabetes (TRIGR) project. Abstract book 4th
immunology of Diabetes Society Congress 1999: 123
MissingFormLabel
- 2
Atkinson M A, MacLaren N K.
The pathogenisis
of insulin-dependent diabetes mellitus.
New England Journal
of Medicine.
1994;
331
1428-1436
MissingFormLabel
- 3
Bingley P J, Bonifacio E, Williams A J, Genovese S, Bottazzo G F, Gale E A.
Prediction of
IDDM in the general population: strategies based on combinations
of autoantibody markers.
Diabetes.
1997;
46
1701-1710
MissingFormLabel
- 4
Bingley P J, Bonifacio E, Ziegler A G, Schatz D A, Atkinson M A, Eisenbarth G S. on behalf of
the Immunology of Diabetes Society .
Proposed Guidelines
on Screening for Risk of Type 1 Diabetes.
Diabetes Care.
2001;
24
398
MissingFormLabel
- 5
Christie M R, Roll U, Payton M A, Hatfield E C, Ziegler A G.
Validity
of screening for individuals at risk for type I diabetes by combined
analysis of antibodies to recombinant proteins.
Diabetes
Care.
1997;
20
965-970
MissingFormLabel
- 6
Dittler J, Seidel D, Schenker M, Ziegler A G.
GADIA2-combi
determination as first-line screening for improved prediction of
type 1 diabetes in relatives.
Diabetes.
1998;
47
592-597
MissingFormLabel
- 7
Feeney S J, Myers M A, Mackay I R, Zimmet P Z, Howard N, Verge C F, Rowley M J.
Evaluation
of ICA512As in combination with other islet cell autoantibodies
at the onset of IDDM.
Diabetes Care.
1997;
20
1403-7
MissingFormLabel
- 8
Füchtenbusch M, Ferber K, Standl E, Ziegler A G.
Prediction
of type 1 diabetes postpartum in patients with gestational diabetes
mellitus by combined islet cell autoantibody screening: a prospective
multicenter study.
Diabetes.
1997;
46
1459-1467
MissingFormLabel
- 9
Füchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler A G.
Delay
of type I diabetes in high risk, first degree relatives by parenteral antigen
administration: The Schwabing Insulin Prophylaxis Pilot Trial.
Diabetologia.
1998;
41
536-541
MissingFormLabel
- 10
Ido Y, Vindigni A, Chang K. et al .
Prevention
of vascular and neural dysfunction in diabetic rats by C-peptide.
Science.
1997;
277
563-566
MissingFormLabel
- 11
Lohmann T, Seissler J, Verlohren H J, Schroder S, Rotger J, Dahn K, Morgenthaler N, Scherbaum W A.
Distinct
genetic and immunological features in patients with onset of IDDM
before and after age 40.
Diabetes Care.
1997;
20
524-529
MissingFormLabel
- 12
Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R.
Prevention of autoimmune
diabetes in NOD mice by 1,25 dihydroxyvitamin D3.
Diabetologia.
1994;
37
552-558
MissingFormLabel
- 13
Rewers M, Bugawan T L, Norris J M, Blair A, Beaty B, Hoffman M, McDuffie R S Jr, Hamman R F, Klingensmith G, Eisenbarth G S, Erlich H A.
Newborn screening
for HLA markers associated with IDDM: diabetes autoimmunity study
in the young (DAISY).
Diabetologia.
1996;
39
807-812
MissingFormLabel
- 14
Roll U, Ziegler A G.
Combined
antibody screening for improved prediction of IDDM - Modern
strategies.
Exp Clin Endocrinol Diabetes.
1997;
105
1-14
MissingFormLabel
- 15
Schatz D, Krischer J, Horne G, Riley W, Spillar R, Silverstein J, Winter W, Muir A, Drovanesian D, Shah S, Malone J, MacLaren N.
Islet
cell antibodies predict insulin-dependent diabetes in United States
school age children as powerfully as in unaffected relatives.
J
Clin Invest.
1994;
93
2403-2407
MissingFormLabel
- 16
Schenker M, Hummel M, Ferber K, Walter M, Keller E, Albert E D, Janka H U, Kastendiek C, Sorger M, Louwen F, Ziegler A G.
Early
expression and high prevalence of islet autoantibodies for DR3/4
heterozygous and DR4/4 homozygous offspring of parents
with Type I diabetes: The German BABYDIAB study.
Diabetologia.
1999;
42
671-677
MissingFormLabel
- 17
Schloot N C, Pozzilli P, Mandrup-Poulsen T.
Immune
markers for monitoring the progression of autoimmune disease.
Diabetes
Metab Res Rev.
1999;
15
141-145
MissingFormLabel
- 18
Seissler J, Hering B, Richter W, Gluck M, Yassin N, Bretzel R G, Boehm B O, Federlin K, Scherbaum W A.
Antibodies
to the M(r) 64,000 (64K) protein in islet cell antibody positive
non-diabetic individuals indicate high risk for impaired beta-cell
function.
Diabetologia.
1992;
35
550-554
MissingFormLabel
- 19
Strebelow M, Schlosser M, Ziegler B, Rjasanowski I, Ziegler M.
Karlsburg Type
I diabetes risk study of a general population: frequencies and interactions
of the four major Type I diabetes-associated autoantibodies studied
in 9419 schoolchildren.
Diabetologia.
1999;
42
661-670
MissingFormLabel
- 20
The Eurodiab Substudy 2 Study
Group .
Vitamin D supplement in early childhood and
risk for Type I (insulin-dependent) diabetes mellitus.
Diabetologia.
1999;
42
51-54
MissingFormLabel
- 21
Verge C F, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Chase H P, Eisenbarth G S.
Number
of autoantibodies (against insulin, GAD or ICA512/IA2)
rather than particular autoantibody specificities determines risk
of type I diabetes.
J Autoimmun.
1996;
9
379-383
MissingFormLabel
- 22
Verge C F, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson R A, Chase H P, Eisenbarth G S.
Prediction
of type I diabetes in first-degree relatives using a combination
of insulin, GAD, and ICA512bdc/IA-2 autoantibodies.
Diabetes.
1996;
45
926-933
MissingFormLabel
- 23
Wahren J, Johansson B L.
Ernst-Friedrich-Pfeiffer
Memorial Lecture. New aspects of C-peptide physiology.
Horm
Metab Res.
1998;
30
A2-5
MissingFormLabel
- 24
Ziegler A G, Hummel M, Schenker M, Bonifacio E.
Autoantibody Appearance
and Risk for the Development of Childhood Diabetes in Offspring of
Parents with Type 1 Diabetes: The German BABY-DIAB Study.
Diabetes.
1999;
48
460-468
MissingFormLabel
Korrespondenz
Prof. Dr. med. Anette-G. Ziegler
Institut für Diabetesforschung und 3.
Med. Abteilung, Krankenhaus München-Schwabing
Kölner Platz 1
80804 München
Phone: 089/30793114
Fax: 089/3081733
Email: prevent.diabetes@lrz.uni-muenchen.de